Interesting facts
Interesting Facts about 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
This compound, with its intricate structure, represents a fascinating area of study in modern chemistry, particularly in medicinal and pharmaceutical fields. Here are some notable aspects:
- Spirans and Scaffold Chemistry: The spirocyclic framework in 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one introduces unique three-dimensional properties that can significantly affect biological activity. Such scaffolds are often examined for their ability to interact with biological targets.
- Tetrazole Moiety: The presence of the tetrazole ring is particularly exciting as compounds containing this moiety are known for their diverse pharmacological activities—including anti-inflammatory and antibacterial properties. The tetrazole's ability to mimic carboxylic acids makes it a valuable asset in drug design.
- Synthetic Versatility: Due to its complex structure, the synthesis of this compound could involve various organic reactions, showcasing the versatility of organic synthesis techniques, from coupling reactions to cycloadditions. Such synthetic routes are essential for developing new medications.
- Biological Engagement: Structurally complex compounds like this one can be screened for biological activity, leading to the potential development of new therapeutics. The specific arrangement of functional groups may influence the compound's binding affinity to target proteins.
- Multifunctionality: The combination of both diaza and spirocyclic elements in this molecule suggests potential multifunctional characteristics, allowing it to interact with multiple biological pathways. This characteristic is critical for compounds intended for advanced therapeutic interventions.
Moreover, ongoing research into compounds like 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one could lead to breakthroughs in understanding complex diseases and developing novel treatments.
Synonyms
irbesartan
138402-11-6
Avapro
Aprovel
Karvea
SR-47436
BMS-186295
Irbesartan BMS
Irbesartan-d3
Irbesartan Zentiva
SR 47436
Sarbevel
BMS 186295
Irbesartan teva
Irbesartan Krka
Irbesartan Winthrop
MFCD00864464
Irbesartan free base
NSC-758696
UNII-J0E2756Z7N
CHEBI:5959
DTXSID0023169
HSDB 8215
J0E2756Z7N
2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
CHEMBL1513
2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
DTXCID903169
1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
AVALIDE COMPONENT IRBESARTAN
Irbesartan [USAN:USP:INN:BAN]
138402-11-6 (free base)
COAPROVEL COMPONENT IRBESARTAN
IFIRMACOMBI COMPONENT IRBESARTAN
NSC 758696
NCGC00095122-01
1185120-76-6
IRBESARTAN (MART.)
IRBESARTAN [MART.]
IRBESARTAN (USP-RS)
IRBESARTAN [USP-RS]
IRBESARTAN (EP IMPURITY)
IRBESARTAN [EP IMPURITY]
IRBESARTAN (EP MONOGRAPH)
IRBESARTAN (USP IMPURITY)
IRBESARTAN [EP MONOGRAPH]
IRBESARTAN [USP IMPURITY]
IRBESARTAN (USP MONOGRAPH)
IRBESARTAN [USP MONOGRAPH]
Irbetan
Irbesartan (USAN:USP:INN:BAN)
[3H]irbesartan
3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
SMR000466306
Avapro (TN)
CAS-138402-11-6
irbesartanum
Irbesartan?
Irbesartan ,(S)
2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
Irbesartan; 2-Butyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
Irbesartan (Avapro)
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
1242281-36-2
2-(~2~H_9_)Butyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
Irbesartan (Standard)
Spectrum_001751
IRBESARTAN [MI]
IRBESARTAN [INN]
IRBESARTAN [JAN]
Spectrum2_001675
Spectrum3_000994
Spectrum4_001122
Spectrum5_001288
IRBESARTAN [USAN]
IRBESARTAN [VANDF]
SCHEMBL4246
IRBESARTAN [WHO-DD]
BSPBio_002687
GTPL589
KBioGR_001603
KBioSS_002231
3-BUTYL-2-[[4-[2-(2H-TETRAZOL-5-YL)PHENYL]PHENYL]METHYL]-2,4-DIAZASPIRO[4.4]NON-3-EN-1-ONE
MLS000759408
MLS001424099
BIDD:GT0347
IRBESARTAN [EMA EPAR]
SPECTRUM1504259
SPBio_001889
GTPL6908
Irbesartan (JP18/USP/INN)
Irbesartan - Bio-X trade mark
IRBESARTAN [ORANGE BOOK]
HY-B0202R
KBio2_002231
KBio2_004799
KBio2_007367
KBio3_001907
C09CA04
BCPP000202
GLXC-04552
HMS1922J05
HMS2051L08
HMS2093E16
HMS2232F23
HMS3370B06
HMS3393L08
HMS3715L04
Pharmakon1600-01504259
BCP02004
HY-B0202
Tox21_111433
AC-537
BDBM50042235
CCG-39091
NSC758696
STK645362
AKOS005576396
AKOS015895353
IRBESARTAN COMPONENT OF AVALIDE
Irbesartan, >=98% (HPLC), powder
Tox21_111433_1
AB07472
BCP9000792
CCG-101012
DB01029
FI24648
KS-1151
NC00262
2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one
IRBESARTAN COMPONENT OF COAPROVEL
IRBESARTAN COMPONENT OF KARVEZIDE
NCGC00095122-02
NCGC00095122-03
NCGC00095122-04
NCGC00095122-05
NCGC00095122-14
2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
BI164582
IRBESARTAN COMPONENT OF IFIRMACOMBI
SY051244
SBI-0206769.P001
I0859
NS00000387
S1507
SR-47436;BMS-186295
C07469
D00523
AB00639954-06
AB00639954_07
AB00639954_08
EN300-37158602
L000319
Q947266
SR-05000001997
SR-05000001997-1
BRD-K60038276-001-02-5
BRD-K60038276-001-03-3
BRD-K60038276-001-08-2
BRD-K60038276-001-09-0
IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN
Irbesartan, European Pharmacopoeia (EP) Reference Standard
IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN
Irbesartan, United States Pharmacopeia (USP) Reference Standard
IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN
Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material
2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
2-Butyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one;BMS-186295;SR-47436
2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one
2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
3-[[2 inverted exclamation mark -(1H-Tetrazol-5-yl)-[1,1 inverted exclamation mark -biphenyl]-4-yl]methyl]-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
Solubility of 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
The solubility characteristics of 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one (C24H20N6O3) are of significant interest due to its complex structure and potential applications.
General Solubility Insights
When examining the solubility of this compound, a few critical factors come into play:
Expected Solubility Characteristics
Given its molecular structure, we might anticipate:
Conclusion
In summary, the solubility of 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one is multifaceted. Further empirical studies are essential to quantify its solubility in various solvents, thereby enhancing our understanding of its potential applications.